Trurx
594 views | +0 today
Follow
Trurx
Keeping the drug industry honest and people informed
Curated by TorHoermanLaw
Your new post is loading...
Your new post is loading...
Scooped by TorHoermanLaw
Scoop.it!

Texas Pradaxa® Rectal Bleeding Lawyer | TX Pradaxa Lawsuit

Texas Pradaxa® Rectal Bleeding Lawyer | TX Pradaxa Lawsuit | Trurx | Scoop.it
If you suffered Pradaxa side effects including rectal bleeding or serious bleeding, contact a lawyer at The Clark Firm, LLP for a Pradaxa lawsuit today.
more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

"Labels Matter" | Just Label It

"Labels Matter" | Just Label It | Trurx | Scoop.it

Okay - I'm all about action today - but, here's another good one.  Sign a petition to FDA Commissioner Margaret Hamburg asking that food labels include when they have genetically engineered ingredients.


No brainer for me - join me?

more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

Big Pharma Routinely Suppresses Data from Clinical Trials — but FDA Approves These Dangerous Drugs Anyway! | Welcome to the Alliance for Natural Health - USA

Big Pharma Routinely Suppresses Data from Clinical Trials — but FDA Approves These Dangerous Drugs Anyway! | Welcome to the Alliance for Natural Health - USA | Trurx | Scoop.it

Alliance for natural health looking for your help to ask for a complete rehaul of the FDA.   Not a bad call - I signed the study and got responses from my fine Senators - anyone want to join me?

more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

Google+: The Complete Guide

Google+: The Complete Guide | Trurx | Scoop.it

Have you all missed it?  Did you see the change at Google?  Maybe you don't pay attention like a marketing person might - but, its a big shift in the results you find when you search anything on Google.  


Basically, Google is investing in social media as the future in information gathering.  And, since Google now has a FB competitor - Google+ and YouTube, you will now find that with everything you search you will find more results with Google products.  


But, take that one step further, Google will now produce search results that will get a prime location on your search from people that post information on your topic in your "Circles" (the Google+ term for "friends").  Wow!  While that may mean nothing to a lot of you - it tells us marketers that we better get our butts to Google+ in a hurry!  


Anyone want to join my "circle?"


more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

J&J Pushed Risperdal for Kids Without Approval, Memo Shows

J&J Pushed Risperdal for Kids Without Approval, Memo Shows | Trurx | Scoop.it
A Johnson & Johnson unit marketed its Risperdal drug in 2004 to doctors working with troubled children even though regulators hadn’t approved the drug for those patients, company records show.
more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

Hacking the BluePrint Cleanse: Same Results at Half the Cost

Hacking the BluePrint Cleanse: Same Results at Half the Cost | Trurx | Scoop.it
The BluePrint Cleanse is a ultra-hip detox program celebrities use to slim down and get red-carpet ready. It uses the power of juice to reset the body.
more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

Latisse for Longer Eyelashes: Safe for Your Eyes?

Latisse for Longer Eyelashes: Safe for Your Eyes? | Trurx | Scoop.it

Have you seen the ads for "Latisse" yet?  


It seems to be the ad I catch most frequently these days, so, I looked into it.  Nightly use of Latisse is supposed to help grow your eyelashes. Great, is this a mascara or a face cream?  


No.  This is a glaucoma drug produced by a drug company - Allergan to be specific.  And, in the tradition of the drug industry, in order to sell drugs for purposes not originally intended, first a market must be found - enter the marketing of "hypotrichosis" or reduced amount of eyelashes and the approval of a drug to cure it by the FDA in 2008 - Latisse.  


Hypotrichosis is not to be confused with hypertrichosis - or werewolf syndrome which also has a drug available for its reversal.  Of course the market for people with werewolf syndrome doesn't pay the bills, and it is now "off patent" so, you won't be seeing any fancy ads out there anytime soon.  But, I digress, back to eyelashes. 


Below you will find a full report on Latisse, with pros and cons on cost, safety, side effects, its ability to give you longer eyelashes, where to buy, etc... One thing caught my eye (no pun intended) was the cost of Latisse - $120/month (although I found it discounted on the web for less than $80/month) and, at least according to this report, your eyelashes will return to normal as soon as you stop using it two times per day.  


No wonder there needs to be a disease connected to Latisse - I can only imagine how many patients have tried to get insurance to cover it, but, as far as I can tell, it has not yet worked.  


Why does this remind me of Restless Leg Syndrome?

...

more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

FDA Law Blog: Supreme Court To Decide When EPA and Perhaps Other Federal Agencies Can be Sued in Federal Court

FDA Law Blog: Supreme Court To Decide When EPA and Perhaps Other Federal Agencies Can be Sued in Federal Court | Trurx | Scoop.it
By JP Ellison – An important issue relating to when an action by an administrative agency can be challenged in court was argued before the Supreme Court last week.
more...
No comment yet.
Scooped by TorHoermanLaw
Scoop.it!

FDA Rejects Dapagliflozin for Type 2 Diabetes

FDA Rejects Dapagliflozin for Type 2 Diabetes | Trurx | Scoop.it

One of the benefits of the Actos uproar has been forcing the FDA to slow down the approval process with the next batch of drugs in the pipeline.  Although dapagliflozin works differently than Actos, it appears to have the same side effects - bladder cancer and, add in, breast cancer risks.   


WASHINGTON -- The FDA said it would not approve the novel diabetes drug dapagliflozin until drugmakers Bristol-Myers Squibb and AstraZeneca supply more data on the drug's benefits and risks.

more...
No comment yet.